-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Rare disease is a disease with a very low incidence and a small number of affected people.
Because the research and development of rare diseases requires a lot of energy and time, and the return rate of drugs after the market is relatively unreasonable, people are willing to be involved in this field.
The business of the enterprise has been very small
.
In recent years, with the increasing attention of rare diseases in the industry and the continuous introduction of some favorable policies by the state to encourage pharmaceutical companies to invest in innovation, the enthusiasm of pharmaceutical companies for research and development has been improved to a certain extent
.
Recently, Condini Pharmaceuticals, a pharmaceutical company focusing on rare diseases, recently submitted a prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong
.
Previously, the pharmaceutical company had launched two sprints, but both failed to pass the listing hearing
.
According to the data, Condini Pharmaceuticals is a company focused on the development, manufacture and distribution of drugs for the treatment of organ fibrosis and other rare and critical diseases
.
Compared with many pharmaceutical companies currently listed in Hong Kong stocks, the company's bright spot is that its products have already been launched for sale.
Its new 1.
1-type drug "Aisi Rui" Pirfenidone Capsules was approved in China in 2011, which is the first domestic IPF (special) drug.
Pulmonary fibrosis) has brought hope and was included in the National Medical Insurance List in 2017
.
According to statistics, the market size of China's IPF treatment in 2020 will be 478 million yuan, of which Aceray will benefit from 437 million yuan, accounting for more than 90% of the market share
.
In addition, Escare is also expanding its indications to other pulmonary fibrotic diseases, including systemic sclerosis-associated interstitial lung disease (SSc-ILD), dermatomyositis-associated interstitial lung disease (DM-ILD), pneumoconiosis and Diseases that cause renal fibrosis
.
In addition to Esri, the company has a rich pipeline of research and development pipelines, including F351, F573, F528, F230 and other products under development, involving liver fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension, and acute and acute-on-chronic liver failure.
sub-therapeutic area
.
Among them, F351, a potential blockbuster drug for the treatment and reversal of chronic hepatitis B-related liver fibrosis, is already in Phase III clinical trials
.
According to relevant statistics, in 2020, the number of patients with liver fibrosis in China has exceeded 130 million, and the market size of anti-hepatic fibrosis drugs in China has exceeded 1 billion yuan
.
At present, there is no effective anti-hepatic fibrosis drug approved in the world.
F351 of Condini Pharmaceuticals is an anti-fibrotic drug candidate with the leading clinical progress in this field in China and around the world
.
The industry believes that if the product is successfully launched, it is expected to become the world's first drug approved for the treatment of chronic hepatitis B-related liver fibrosis, and to achieve faster development in the domestic market
.
The anti-hepatic fibrosis drug market is expected to increase to 5.
429 billion yuan by 2031
.
It is worth mentioning that, from the perspective of financial data, after Kangdini Pharmaceuticals launched its mature products, although the revenue and profits were considerable, the R&D investment was not high
.
In 2019, 2020 and the first three quarters of 2021, the company's total revenue was 325 million yuan, 447 million yuan and 440 million yuan respectively; net profit was 70.
1 million yuan, 128 million yuan and 126 million yuan respectively
.
However, in the same period, the R&D expenses were 15.
85 million yuan, 37.
212 million yuan and 33.
17 million yuan respectively, accounting for only 4.
9%, 8.
3% and 7.
5% of the total revenue
.
Previously, Condini Pharmaceutical had launched three sprints to the Hong Kong Stock Exchange, but the first two failed
.
It remains to be seen whether Condini Pharmaceuticals will resume its IPO in Hong Kong this time
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Because the research and development of rare diseases requires a lot of energy and time, and the return rate of drugs after the market is relatively unreasonable, people are willing to be involved in this field.
The business of the enterprise has been very small
.
In recent years, with the increasing attention of rare diseases in the industry and the continuous introduction of some favorable policies by the state to encourage pharmaceutical companies to invest in innovation, the enthusiasm of pharmaceutical companies for research and development has been improved to a certain extent
.
Recently, Condini Pharmaceuticals, a pharmaceutical company focusing on rare diseases, recently submitted a prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong
.
Previously, the pharmaceutical company had launched two sprints, but both failed to pass the listing hearing
.
According to the data, Condini Pharmaceuticals is a company focused on the development, manufacture and distribution of drugs for the treatment of organ fibrosis and other rare and critical diseases
.
Compared with many pharmaceutical companies currently listed in Hong Kong stocks, the company's bright spot is that its products have already been launched for sale.
Its new 1.
1-type drug "Aisi Rui" Pirfenidone Capsules was approved in China in 2011, which is the first domestic IPF (special) drug.
Pulmonary fibrosis) has brought hope and was included in the National Medical Insurance List in 2017
.
According to statistics, the market size of China's IPF treatment in 2020 will be 478 million yuan, of which Aceray will benefit from 437 million yuan, accounting for more than 90% of the market share
.
In addition, Escare is also expanding its indications to other pulmonary fibrotic diseases, including systemic sclerosis-associated interstitial lung disease (SSc-ILD), dermatomyositis-associated interstitial lung disease (DM-ILD), pneumoconiosis and Diseases that cause renal fibrosis
.
In addition to Esri, the company has a rich pipeline of research and development pipelines, including F351, F573, F528, F230 and other products under development, involving liver fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension, and acute and acute-on-chronic liver failure.
sub-therapeutic area
.
Among them, F351, a potential blockbuster drug for the treatment and reversal of chronic hepatitis B-related liver fibrosis, is already in Phase III clinical trials
.
According to relevant statistics, in 2020, the number of patients with liver fibrosis in China has exceeded 130 million, and the market size of anti-hepatic fibrosis drugs in China has exceeded 1 billion yuan
.
At present, there is no effective anti-hepatic fibrosis drug approved in the world.
F351 of Condini Pharmaceuticals is an anti-fibrotic drug candidate with the leading clinical progress in this field in China and around the world
.
The industry believes that if the product is successfully launched, it is expected to become the world's first drug approved for the treatment of chronic hepatitis B-related liver fibrosis, and to achieve faster development in the domestic market
.
The anti-hepatic fibrosis drug market is expected to increase to 5.
429 billion yuan by 2031
.
It is worth mentioning that, from the perspective of financial data, after Kangdini Pharmaceuticals launched its mature products, although the revenue and profits were considerable, the R&D investment was not high
.
In 2019, 2020 and the first three quarters of 2021, the company's total revenue was 325 million yuan, 447 million yuan and 440 million yuan respectively; net profit was 70.
1 million yuan, 128 million yuan and 126 million yuan respectively
.
However, in the same period, the R&D expenses were 15.
85 million yuan, 37.
212 million yuan and 33.
17 million yuan respectively, accounting for only 4.
9%, 8.
3% and 7.
5% of the total revenue
.
Previously, Condini Pharmaceutical had launched three sprints to the Hong Kong Stock Exchange, but the first two failed
.
It remains to be seen whether Condini Pharmaceuticals will resume its IPO in Hong Kong this time
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
